Hüttemann, E.; Muzalyova, A.; Gröhl, K.; Nagl, S.; Fleischmann, C.; Ebigbo, A.; Classen, J.; Wanzl, J.; Prinz, F.; Mayr, P.;
et al. Efficacy and Safety of Vedolizumab in Patients with Inflammatory Bowel Disease in Association with Vedolizumab Drug Levels. J. Clin. Med. 2024, 13, 140.
https://doi.org/10.3390/jcm13010140
AMA Style
Hüttemann E, Muzalyova A, Gröhl K, Nagl S, Fleischmann C, Ebigbo A, Classen J, Wanzl J, Prinz F, Mayr P,
et al. Efficacy and Safety of Vedolizumab in Patients with Inflammatory Bowel Disease in Association with Vedolizumab Drug Levels. Journal of Clinical Medicine. 2024; 13(1):140.
https://doi.org/10.3390/jcm13010140
Chicago/Turabian Style
Hüttemann, Eva, Anna Muzalyova, Katharina Gröhl, Sandra Nagl, Carola Fleischmann, Alanna Ebigbo, Johanna Classen, Julia Wanzl, Friederike Prinz, Patrick Mayr,
and et al. 2024. "Efficacy and Safety of Vedolizumab in Patients with Inflammatory Bowel Disease in Association with Vedolizumab Drug Levels" Journal of Clinical Medicine 13, no. 1: 140.
https://doi.org/10.3390/jcm13010140
APA Style
Hüttemann, E., Muzalyova, A., Gröhl, K., Nagl, S., Fleischmann, C., Ebigbo, A., Classen, J., Wanzl, J., Prinz, F., Mayr, P., & Schnoy, E.
(2024). Efficacy and Safety of Vedolizumab in Patients with Inflammatory Bowel Disease in Association with Vedolizumab Drug Levels. Journal of Clinical Medicine, 13(1), 140.
https://doi.org/10.3390/jcm13010140
